{"symbol": "ABBV", "publishedDate": "2021-04-23 04:34:11", "publisher": "Seeking Alpha", "title": "An Introduction To 'Buckets' For DGI Investors", "image": "https://images.financialmodelingprep.com/news/an-introduction-to-buckets-for-dgi-investors-20210423.jpg", "site": "seekingalpha.com", "text": "Many DGI investors have goals focused on income and growing the dividend stream. Their portfolio strategy should reflect these goals.", "url": "https://seekingalpha.com/article/4420834-introduction-to-buckets-dgi-investors", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-23T04:34:11-04:00", "date_et": "2021-04-23"}
{"symbol": "ABBV", "publishedDate": "2021-04-23 08:00:00", "publisher": "PRNewsWire", "title": "AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy", "image": "https://images.financialmodelingprep.com/news/abbvie-receives-positive-chmp-opinion-for-venclyxto-venetoclax-as-20210423.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill., April 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VENCLYXTO® (venetoclax) in combination with hypomethylating agents for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.", "url": "https://www.prnewswire.com/news-releases/abbvie-receives-positive-chmp-opinion-for-venclyxto-venetoclax-as-a-combination-regimen-for-adult-patients-with-newly-diagnosed-acute-myeloid-leukemia-who-are-ineligible-for-intensive-chemotherapy-301275874.html", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-23T08:00:00-04:00", "date_et": "2021-04-23"}
{"symbol": "ABBV", "publishedDate": "2021-04-23 10:31:19", "publisher": "Zacks Investment Research", "title": "What's in the Cards for AbbVie (ABBV) This Earnings Season?", "image": "https://images.financialmodelingprep.com/news/whats-in-the-cards-for-abbvie-abbv-this-earnings-20210423.jpg", "site": "zacks.com", "text": "Higher demand for its growth drugs is likely to have offset generic competition for Humira in the United States to boost AbbVie's (ABBV) first-quarter sales.", "url": "https://www.zacks.com/stock/news/1441726/whats-in-the-cards-for-abbvie-abbv-this-earnings-season", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-23T10:31:19-04:00", "date_et": "2021-04-23"}
{"symbol": "ABBV", "publishedDate": "2021-04-24 06:04:00", "publisher": "The Motley Fool", "title": "3 Bargain Stocks to Buy With the Market Near All-Time Highs", "image": "https://images.financialmodelingprep.com/news/3-bargain-stocks-to-buy-with-the-market-near-alltime-20210424.jpg", "site": "fool.com", "text": "Not every stock is ridiculously expensive right now.", "url": "https://www.fool.com/investing/2021/04/24/3-bargain-stocks-to-buy-with-the-market-near-all-t/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-24T06:04:00-04:00", "date_et": "2021-04-24"}
{"symbol": "ABBV", "publishedDate": "2021-04-26 18:17:10", "publisher": "Zacks Investment Research", "title": "AbbVie (ABBV) Gains But Lags Market: What You Should Know", "image": "https://images.financialmodelingprep.com/news/abbvie-abbv-gains-but-lags-market-what-you-should-20210426.jpg", "site": "zacks.com", "text": "In the latest trading session, AbbVie (ABBV) closed at $111.39, marking a +0.01% move from the previous day.", "url": "https://www.zacks.com/stock/news/1458006/abbvie-abbv-gains-but-lags-market-what-you-should-know", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-26T18:17:10-04:00", "date_et": "2021-04-26"}
{"symbol": "ABBV", "publishedDate": "2021-04-27 06:22:00", "publisher": "The Motley Fool", "title": "This Pharma Giant Lost the Vaccine Race, But Its COVID-19 Journey May Not Be Over", "image": "https://images.financialmodelingprep.com/news/this-pharma-giant-lost-the-vaccine-race-but-its-20210427.jpg", "site": "fool.com", "text": "Its vaccine might not have panned out as expected, but Merck has more in the works.", "url": "https://www.fool.com/investing/2021/04/27/this-pharma-giant-lost-the-vaccine-race-but-its-co/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-27T06:22:00-04:00", "date_et": "2021-04-27"}
{"symbol": "ABBV", "publishedDate": "2021-04-27 08:30:00", "publisher": "PRNewsWire", "title": "Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting", "image": "https://images.financialmodelingprep.com/news/allergan-an-abbvie-company-to-share-new-data-highlighting-20210427.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill., April 27, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new data, including real-world evidence, and patient-reported outcomes (PROs) for products across its eye care portfolio and pipeline at the ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting (May 1-7).", "url": "https://www.prnewswire.com/news-releases/allergan-an-abbvie-company-to-share-new-data-highlighting-latest-advancements-in-eye-care-at-arvo-association-for-research-in-vision-and-ophthalmology-2021-annual-virtual-meeting-301276238.html", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-27T08:30:00-04:00", "date_et": "2021-04-27"}
{"symbol": "ABBV", "publishedDate": "2021-04-27 17:06:00", "publisher": "GuruFocus", "title": "Top Pharma Giants Expected to Be Most Active in M&A", "image": "https://images.financialmodelingprep.com/news/top-pharma-giants-expected-to-be-most-active-in-20210427.jpg", "site": "gurufocus.com", "text": "Companies likely seeking bolt-on acquisitions, not mega-deals", "url": "https://www.gurufocus.com/news/1408507/top-pharma-giants-expected-to-be-most-active-in-ma", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-27T17:06:00-04:00", "date_et": "2021-04-27"}
{"symbol": "ABBV", "publishedDate": "2021-04-27 17:07:07", "publisher": "Marijuana Stocks", "title": "Top Medical Marijuana Stocks In 2021? 2 For Your May Watchlist", "image": "https://images.financialmodelingprep.com/news/top-medical-marijuana-stocks-in-2021-2-for-your-may-20210427.jpg", "site": "marijuanastocks.com", "text": "Are Medical Marijuana Stock Going To Make Investors Rich In The Future? The post Top Medical Marijuana Stocks In 2021? 2 For Your May Watchlist appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.", "url": "https://marijuanastocks.com/top-medical-marijuana-stocks-in-2021-2-for-your-may-watchlist/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-27T17:07:07-04:00", "date_et": "2021-04-27"}
{"symbol": "ABBV", "publishedDate": "2021-04-28 12:17:17", "publisher": "Zacks Investment Research", "title": "This is Why AbbVie (ABBV) is a Great Dividend Stock", "image": "https://images.financialmodelingprep.com/news/this-is-why-abbvie-abbv-is-a-great-dividend-stock-20210428.jpg", "site": "zacks.com", "text": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?", "url": "https://www.zacks.com/stock/news/1467601/this-is-why-abbvie-abbv-is-a-great-dividend-stock", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-28T12:17:17-04:00", "date_et": "2021-04-28"}
{"symbol": "ABBV", "publishedDate": "2021-04-28 12:17:27", "publisher": "Zacks Investment Research", "title": "Strong New Drugs Sales to Aid AbbVie's (ABBV) Q1 Earnings", "image": "https://images.financialmodelingprep.com/news/strong-new-drugs-sales-to-aid-abbvies-abbv-q1-20210428.jpg", "site": "zacks.com", "text": "AbbVie (ABBV) is expected to have witnessed a recovery in demand trends for new drugs amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.", "url": "https://www.zacks.com/stock/news/1467743/strong-new-drugs-sales-to-aid-abbvies-abbv-q1-earnings", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-28T12:17:27-04:00", "date_et": "2021-04-28"}
{"symbol": "ABBV", "publishedDate": "2021-04-28 13:02:22", "publisher": "Zacks Investment Research", "title": "Healthcare ETFs on Radar As Q1 Earnings Unfold", "image": "https://images.financialmodelingprep.com/news/healthcare-etfs-on-radar-as-q1-earnings-unfold-20210428.jpg", "site": "zacks.com", "text": "Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.", "url": "https://www.zacks.com/stock/news/1467714/healthcare-etfs-on-radar-as-q1-earnings-unfold", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-28T13:02:22-04:00", "date_et": "2021-04-28"}
{"symbol": "ABBV", "publishedDate": "2021-04-28 13:18:06", "publisher": "Seeking Alpha", "title": "Update: 91 'Top Dividend Stocks On Earth' For May", "image": "https://images.financialmodelingprep.com/news/update-91-top-dividend-stocks-on-earth-for-may-20210428.jpg", "site": "seekingalpha.com", "text": "Kiplinger \"insights for investors\" online first offered this list of 91 \"Top Dividend Stocks From Around The World\" July 13, 2020. Data updated 4/26/21 flagged 13 yields ripe with upside. These International “Dividend Aristocrats” have raised dividends at least five straight years (Canadian), 10 years (European Union), or 25 years (U.S. companies).", "url": "https://seekingalpha.com/article/4422008-update-91-top-dividend-stocks-on-earth-for-may", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-28T13:18:06-04:00", "date_et": "2021-04-28"}
{"symbol": "ABBV", "publishedDate": "2021-04-28 16:47:02", "publisher": "Zacks Investment Research", "title": "5 Big Cap Earnings Superstars", "image": "https://images.financialmodelingprep.com/news/5-big-cap-earnings-superstars-20210428.jpg", "site": "zacks.com", "text": "It's not easy for companies to beat on earnings nearly every quarter for years but these five are doing it.", "url": "https://www.zacks.com/stock/news/1468976/5-big-cap-earnings-superstars", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-28T16:47:02-04:00", "date_et": "2021-04-28"}
{"symbol": "ABBV", "publishedDate": "2021-04-28 17:56:57", "publisher": "The Motley Fool", "title": "Is AbbVie a Buy Before Its Earnings Report Friday?", "image": "https://images.financialmodelingprep.com/news/is-abbvie-a-buy-before-its-earnings-report-friday-20210428.jpg", "site": "fool.com", "text": "How the pharma company progresses on its pivot away from Humira will have a large impact on the stock's reaction.", "url": "https://www.fool.com/investing/2021/04/28/is-abbvie-a-buy-before-its-earnings-report-friday/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-28T17:56:57-04:00", "date_et": "2021-04-28"}
{"symbol": "ABBV", "publishedDate": "2021-04-29 06:00:37", "publisher": "InvestorPlace", "title": "7 Pharmaceutical Stocks To Buy For Valuation Plus Solid Dividends", "image": "https://images.financialmodelingprep.com/news/7-pharmaceutical-stocks-to-buy-for-valuation-plus-solid-20210429.jpg", "site": "investorplace.com", "text": "High-quality pharmaceutical stocks comes with steady business, low valuations and solid dividend. Let's look at a handful of them now.", "url": "https://investorplace.com/2021/04/7-pharmaceutical-stocks-to-buy-for-valuation-plus-solid-dividends/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-29T06:00:37-04:00", "date_et": "2021-04-29"}
{"symbol": "ABBV", "publishedDate": "2021-04-29 10:16:10", "publisher": "Benzinga", "title": "A Preview Of AbbVie's Earnings", "image": "https://images.financialmodelingprep.com/news/a-preview-of-abbvies-earnings-20210429.jpg", "site": "benzinga.com", "text": "AbbVie (NYSE:ABBV) unveils its next round of earnings this Friday, April 30. Get prepared with Benzinga's ultimate preview for AbbVie's Q1 earnings.", "url": "https://www.benzinga.com/news/earnings/21/04/20864994/a-preview-of-abbvies-earnings", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-29T10:16:10-04:00", "date_et": "2021-04-29"}
{"symbol": "ABBV", "publishedDate": "2021-04-29 16:21:51", "publisher": "GuruFocus", "title": "AstraZeneca, Merck, AbbVie Struck Biggest Licensing Deals in 2020", "image": "https://images.financialmodelingprep.com/news/astrazeneca-merck-abbvie-struck-biggest-licensing-deals-in-2020-20210429.jpg", "site": "gurufocus.com", "text": "In my April 27 discussion, I looked at the pharmaceutical companies that are most likely to pursue acquisitions this year, with activity forecasted to pick up after a down 2020. While the pandemic contributed to the slowdown in merger and acquisitions, licensing arrangements fared far better, coming in relatively flat at a total value of about $40 billion", "url": "https://www.gurufocus.com/news/1411391/astrazeneca-merck-abbvie-struck-biggest-licensing-deals-in-2020", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-29T16:21:51-04:00", "date_et": "2021-04-29"}
{"symbol": "ABBV", "publishedDate": "2021-04-30 07:42:00", "publisher": "PRNewsWire", "title": "AbbVie Reports First-Quarter 2021 Financial Results", "image": "https://images.financialmodelingprep.com/news/abbvie-reports-firstquarter-2021-financial-results-20210430.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill., April 30, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021.", "url": "https://www.prnewswire.com/news-releases/abbvie-reports-first-quarter-2021-financial-results-301281124.html", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-30T07:42:00-04:00", "date_et": "2021-04-30"}
{"symbol": "ABBV", "publishedDate": "2021-04-30 07:51:00", "publisher": "Reuters", "title": "AbbVie raises full-year profit forecast as Humira fuels sales beat", "image": "https://images.financialmodelingprep.com/news/abbvie-raises-fullyear-profit-forecast-as-humira-fuels-sales-20210430.jpg", "site": "reuters.com", "text": "AbbVie Inc beat Wall Street estimates for first-quarter revenue on Friday and raised its full-year profit forecast, helped by demand for blockbuster rheumatoid arthritis drug Humira and newer treatments such as psoriasis treatment Skyrizi.", "url": "https://www.reuters.com/article/us-abbvie-results/abbvie-raises-full-year-profit-forecast-as-humira-fuels-sales-beat-idUSKBN2CH1GS", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-30T07:51:00-04:00", "date_et": "2021-04-30"}
{"symbol": "ABBV", "publishedDate": "2021-04-30 08:00:54", "publisher": "Benzinga", "title": "AbbVie: Q1 Earnings Insights", "image": "https://images.financialmodelingprep.com/news/abbvie-q1-earnings-insights-20210430.jpg", "site": "benzinga.com", "text": "Shares of AbbVie (NYSE:ABBV) rose 1.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 21.90% over the past year to $2.95, which beat the estimate of $2.83.", "url": "https://www.benzinga.com/news/earnings/21/04/20886199/abbvie-q1-earnings-insights", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-30T08:00:54-04:00", "date_et": "2021-04-30"}
{"symbol": "ABBV", "publishedDate": "2021-04-30 08:17:00", "publisher": "The Motley Fool", "title": "3 Warren Buffett Stocks Worth Buying Now", "image": "https://images.financialmodelingprep.com/news/3-warren-buffett-stocks-worth-buying-now-20210430.jpg", "site": "fool.com", "text": "Borrow a tip from the best-known name in the stock-picking business.", "url": "https://www.fool.com/investing/2021/04/30/3-warren-buffett-stocks-worth-buying-now/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-30T08:17:00-04:00", "date_et": "2021-04-30"}
{"symbol": "ABBV", "publishedDate": "2021-04-30 08:18:28", "publisher": "Market Watch", "title": "AbbVie's stock is up 2.0% as Humira sales top $3.9 billion in sales in the first quarter", "image": "https://images.financialmodelingprep.com/news/abbvies-stock-is-up-20-as-humira-sales-top-20210430.jpg", "site": "marketwatch.com", "text": "Shares of AbbVie Inc. gained 2.0% in premarket trading on Friday after it beat earnings expectations and saw a noticeable jump in pharmaceutical revenue for the first quarter of 2021. The diagnostics company had earnings of $3.5 billion, or $1.99 earnings per share, in the first quarter of 2021, compared with $3.0 billion, or $2.02 earnings per share, in the same quarter a year ago.", "url": "https://www.marketwatch.com/story/abbvies-stock-is-up-20-as-humira-sales-top-39-billion-in-sales-in-the-first-quarter-2021-04-30", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-30T08:18:28-04:00", "date_et": "2021-04-30"}
{"symbol": "ABBV", "publishedDate": "2021-04-30 09:17:48", "publisher": "Benzinga", "title": "AbbVie Beats Q1 Earnings On Strong Humira Sales, Raises Full-Year Profit Forecast", "image": "https://images.financialmodelingprep.com/news/abbvie-beats-q1-earnings-on-strong-humira-sales-raises-20210430.jpg", "site": "benzinga.com", "text": "AbbVie Inc (NYSE: ABBV) beat Wall Street consensus for first-quarter revenue & earnings and raised its full-year profit forecast, helped by demand for its rheumatoid arthritis drug, Humira, and newer treatments such as psoriasis treatment Skyrizi. It reported an adjusted EPS of $2.95, which beat the analyst consensus estimate of $2.83", "url": "https://www.benzinga.com/news/earnings/21/04/20887535/abbvie-beats-q1-earnings-on-strong-humira-sales-raises-full-year-profit-forecast", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-30T09:17:48-04:00", "date_et": "2021-04-30"}
{"symbol": "ABBV", "publishedDate": "2021-04-30 10:35:19", "publisher": "The Motley Fool", "title": "How AbbVie Beat Expectations Again in Q1", "image": "https://images.financialmodelingprep.com/news/how-abbvie-beat-expectations-again-in-q1-20210430.jpg", "site": "fool.com", "text": "Humira is still the main star for now, but the company's newer drugs are gaining momentum.", "url": "https://www.fool.com/investing/2021/04/30/how-abbvie-beat-expectations-again-in-q1/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-30T10:35:19-04:00", "date_et": "2021-04-30"}
{"symbol": "ABBV", "publishedDate": "2021-04-30 12:01:20", "publisher": "Zacks Investment Research", "title": "AbbVie (ABBV) Beats on Q1 Earnings, Raises 2021 Guidance", "image": "https://images.financialmodelingprep.com/news/abbvie-abbv-beats-on-q1-earnings-raises-2021-guidance-20210430.jpg", "site": "zacks.com", "text": "AbbVie (ABBV) beats on first-quarter 2021 earnings and revenues. Shares up in pre-market trading.", "url": "https://www.zacks.com/stock/news/1479453/abbvie-abbv-beats-on-q1-earnings-raises-2021-guidance", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-30T12:01:20-04:00", "date_et": "2021-04-30"}
{"symbol": "ABBV", "publishedDate": "2021-04-30 15:08:04", "publisher": "Seeking Alpha", "title": "AbbVie (ABBV) CEO, Rick Gonzalez on Q1 2021 Results - Earnings Call Transcript", "image": "https://images.financialmodelingprep.com/news/abbvie-abbv-ceo-rick-gonzalez-on-q1-2021-results-earnings-20210430.jpg", "site": "seekingalpha.com", "text": "AbbVie (ABBV) CEO, Rick Gonzalez on Q1 2021 Results - Earnings Call Transcript", "url": "https://seekingalpha.com/article/4423075-abbvie-abbv-ceo-rick-gonzalez-on-q1-2021-results-earnings-call-transcript", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-30T15:08:04-04:00", "date_et": "2021-04-30"}
{"symbol": "ABBV", "publishedDate": "2021-04-30 15:18:09", "publisher": "InvestorPlace", "title": "7 Value Stocks You Want In Your Life", "image": "https://images.financialmodelingprep.com/news/7-value-stocks-you-want-in-your-life-20210430.jpg", "site": "investorplace.com", "text": "Although growth-related investments have been all the rage, smart investors should see the potential in buying value stocks. The post 7 Value Stocks You Want In Your Life appeared first on InvestorPlace.", "url": "https://investorplace.com/2021/04/7-value-stocks-you-want-in-your-life/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-30T15:18:09-04:00", "date_et": "2021-04-30"}
{"symbol": "ABBV", "publishedDate": "2021-04-30 16:27:00", "publisher": "The Motley Fool", "title": "AbbVie Rises on Q1 Beats, Raised EPS Guidance", "image": "https://images.financialmodelingprep.com/news/abbvie-rises-on-q1-beats-raised-eps-guidance-20210430.jpg", "site": "fool.com", "text": "The company is excited about its prospects for the remainder of this year.", "url": "https://www.fool.com/investing/2021/04/30/abbvie-rises-on-q1-beats-raised-eps-guidance/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-04-30T16:27:00-04:00", "date_et": "2021-04-30"}
{"symbol": "ABBV", "publishedDate": "2021-05-01 06:50:00", "publisher": "The Motley Fool", "title": "Better Buy for 2021: AbbVie or Merck?", "image": "https://images.financialmodelingprep.com/news/better-buy-for-2021-abbvie-or-merck-20210501.jpg", "site": "fool.com", "text": "Which company should you consider buying right now?", "url": "https://www.fool.com/investing/2021/05/01/better-buy-for-2021-abbvie-or-merck/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-01T06:50:00-04:00", "date_et": "2021-05-01"}
{"symbol": "ABBV", "publishedDate": "2021-05-02 06:03:00", "publisher": "The Motley Fool", "title": "Warren Buffett's 3 Highest-Yielding Dividend Stocks", "image": "https://images.financialmodelingprep.com/news/warren-buffetts-3-highestyielding-dividend-stocks-20210502.jpg", "site": "fool.com", "text": "Here's why they could be attractive to most income-seeking investors.", "url": "https://www.fool.com/investing/2021/05/02/warren-buffetts-3-highest-yielding-dividend-stocks/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-02T06:03:00-04:00", "date_et": "2021-05-02"}
{"symbol": "ABBV", "publishedDate": "2021-05-02 08:22:22", "publisher": "Pulse2", "title": "ABBV Stock: $124 Target (Up From $120) By Piper Sandler", "image": "https://images.financialmodelingprep.com/news/abbv-stock-124-target-up-from-120-by-piper-20210502.jpg", "site": "pulse2.com", "text": "The shares of AbbVie Inc (NYSE: ABBV) have received a price target increase from $120 to $124 by Piper Sandler. These are the details.", "url": "https://pulse2.com/abbv-stock-nyse-abbvie-124-target-up-from-120-by-piper-sandler/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-02T08:22:22-04:00", "date_et": "2021-05-02"}
{"symbol": "ABBV", "publishedDate": "2021-05-02 21:50:35", "publisher": "Seeking Alpha", "title": "AbbVie's Earnings Beat Reaffirms A Bullish Outlook", "image": "https://images.financialmodelingprep.com/news/abbvies-earnings-beat-reaffirms-a-bullish-outlook-20210502.jpg", "site": "seekingalpha.com", "text": "AbbVie just reported solid quarterly performance. The stock is cheap relative to (admittedly modest) expected earnings.", "url": "https://seekingalpha.com/article/4423647-abbvies-earnings-beat-reaffirms-bullish-outlook", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-02T21:50:35-04:00", "date_et": "2021-05-02"}
{"symbol": "ABBV", "publishedDate": "2021-05-02 23:16:37", "publisher": "Seeking Alpha", "title": "AbbVie: A Money Minting Machine", "image": "https://images.financialmodelingprep.com/news/abbvie-a-money-minting-machine-20210502.jpg", "site": "seekingalpha.com", "text": "While only the U.S. Department of Treasury is authorized to mint paper and coin money, there are some publicly traded businesses that figuratively do so with their high margins. One such business is AbbVie, which generated a staggering net margin (net earnings/net revenues) of 27.3% during Q1 2021.", "url": "https://seekingalpha.com/article/4423651-abbvie-a-money-minting-machine", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-02T23:16:37-04:00", "date_et": "2021-05-02"}
{"symbol": "ABBV", "publishedDate": "2021-05-03 09:47:55", "publisher": "GuruFocus", "title": "3 High-Yield Stocks for Dividend Investors", "image": "https://images.financialmodelingprep.com/news/3-highyield-stocks-for-dividend-investors-20210503.jpg", "site": "gurufocus.com", "text": "The following three stocks may be of interest to dividend investors, as they are offering much higher dividend yields than the S&P 500 Index. The benchmark index's dividend yields 1.38% as of Friday, April 30.", "url": "https://www.gurufocus.com/news/1413770/3-highyield-stocks-for-dividend-investors-", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-03T09:47:55-04:00", "date_et": "2021-05-03"}
{"symbol": "ABBV", "publishedDate": "2021-05-03 11:16:21", "publisher": "Zacks Investment Research", "title": "3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes", "image": "https://images.financialmodelingprep.com/news/3-big-drugmaker-stocks-to-watch-out-for-amid-20210503.jpg", "site": "zacks.com", "text": "3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes", "url": "https://www.zacks.com/commentary/1492454/3-big-drugmaker-stocks-to-watch-out-for-amid-pandemic-woes", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-03T11:16:21-04:00", "date_et": "2021-05-03"}
{"symbol": "ABBV", "publishedDate": "2021-05-03 14:25:31", "publisher": "InvestorPlace", "title": "3 Top Stock Trades for the Week", "image": "https://images.financialmodelingprep.com/news/3-top-stock-trades-for-the-week-20210503.jpg", "site": "investorplace.com", "text": "This week's top stock trades include three low-risk entries for bulls: NUE, AEM and ABBV. This trio boasts better patterns than the S&P 500.", "url": "https://investorplace.com/3-top-stock-trades-for-the-new-week/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-03T14:25:31-04:00", "date_et": "2021-05-03"}
{"symbol": "ABBV", "publishedDate": "2021-05-03 17:40:14", "publisher": "GuruFocus", "title": "AbbVie's Humira Still Number 1 in Drug Sales", "image": "https://images.financialmodelingprep.com/news/abbvies-humira-still-number-1-in-drug-sales-20210503.jpg", "site": "gurufocus.com", "text": "Humira retained the top spot on the list of the top 20 selling drugs in 2020. The AbbVie , Financial)\">Inc.( ABBV , Financial) mega-blockbuster generated revenue of nearly $20.4 billion last year, according to an article in FierceBiotech, which worked with Evaluate Pharma to compile the list.", "url": "https://www.gurufocus.com/news/1414257/abbvies-humira-still-number-1-in-drug-sales", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-03T17:40:14-04:00", "date_et": "2021-05-03"}
{"symbol": "ABBV", "publishedDate": "2021-05-04 03:37:15", "publisher": "Seeking Alpha", "title": "Kiplinger And Barron's 75 Top Stocks For 2021 Show 17 As May Flies", "image": "https://images.financialmodelingprep.com/news/kiplinger-and-barrons-75-top-stocks-for-2021-show-20210504.jpg", "site": "seekingalpha.com", "text": "October-December Kiplinger Today published four articles: 11 Best Monthly Dividend[s], 21 Best Stocks, 11 Dividend Growth Stocks, and 25 Dividend Stocks Analysts Love. Stocks therein I called \"Kiplinger Top Stocks For 2021.\" Then, in March, Barron's Weekly published Retire on Dividends listing 10 to start. All told, five Kip/Bar articles listed 78 stocks. Three duplicates left 75, with 66 paying dividends.", "url": "https://seekingalpha.com/article/4423926-kiplinger-barrons-75-top-stocks-for-2021-show-17-may-flies", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-04T03:37:15-04:00", "date_et": "2021-05-04"}
{"symbol": "ABBV", "publishedDate": "2021-05-04 18:47:38", "publisher": "Zacks Investment Research", "title": "AbbVie (ABBV) Stock Moves -0.61%: What You Should Know", "image": "https://images.financialmodelingprep.com/news/abbvie-abbv-stock-moves-061-what-you-should-know-20210504.jpg", "site": "zacks.com", "text": "AbbVie (ABBV) closed at $113.98 in the latest trading session, marking a -0.61% move from the prior day.", "url": "https://www.zacks.com/stock/news/1500786/abbvie-abbv-stock-moves-061-what-you-should-know", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-04T18:47:38-04:00", "date_et": "2021-05-04"}
{"symbol": "ABBV", "publishedDate": "2021-05-04 22:26:24", "publisher": "Seeking Alpha", "title": "5 High-Yield ESG Blue-Chips For A Safe And Prosperous Retirement", "image": "https://images.financialmodelingprep.com/news/5-highyield-esg-bluechips-for-a-safe-and-prosperous-20210504.jpg", "site": "seekingalpha.com", "text": "ESG investing has become red hot in recent years, and $20 trillion of assets are expected to flow into ESG funds in the next two decades. Some think ESG is the newest alpha factor. Thus far studies show it's merely an indicator of overall fundamental risk and quality, similar to credit ratings.", "url": "https://seekingalpha.com/article/4424316-philip-morris-enbridge-abbvie-prudential-manulife-high-yield-esg-blue-chips-for-a-rich-retirement", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-04T22:26:24-04:00", "date_et": "2021-05-04"}
{"symbol": "ABBV", "publishedDate": "2021-05-05 12:24:28", "publisher": "Zacks Investment Research", "title": "Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?", "image": "https://images.financialmodelingprep.com/news/has-abbvie-abbv-outpaced-other-medical-stocks-this-year-20210505.jpg", "site": "zacks.com", "text": "Is (ABBV) Outperforming Other Medical Stocks This Year?", "url": "https://www.zacks.com/stock/news/1504919/has-abbvie-abbv-outpaced-other-medical-stocks-this-year", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-05T12:24:28-04:00", "date_et": "2021-05-05"}
{"symbol": "ABBV", "publishedDate": "2021-05-05 15:40:55", "publisher": "GuruFocus", "title": "Diamond Hill Capital Reveals Top 1st-Quarter Trades", "image": "https://images.financialmodelingprep.com/news/diamond-hill-capital-reveals-top-1stquarter-trades-20210505.jpg", "site": "gurufocus.com", "text": "Earlier this week, investment firm Diamond Hill Capital (Trades, Portfolio) disclosed its portfolio for the first quarter, which ended March 31.", "url": "https://www.gurufocus.com/news/1417090/diamond-hill-capital-reveals-top-1stquarter-trades", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-05T15:40:55-04:00", "date_et": "2021-05-05"}
{"symbol": "ABBV", "publishedDate": "2021-05-07 13:13:44", "publisher": "InvestorPlace", "title": "7 Warren Buffett Stocks to Buy for the Next Decade", "image": "https://images.financialmodelingprep.com/news/7-warren-buffett-stocks-to-buy-for-the-next-20210507.jpg", "site": "investorplace.com", "text": "As one of the world's greatest investors, Warren Buffett knows a thing or two about acquiring the best stocks to buy. The post 7 Warren Buffett Stocks to Buy for the Next Decade appeared first on InvestorPlace.", "url": "https://investorplace.com/2021/05/7-warren-buffett-stocks-to-buy-for-next-decade/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-07T13:13:44-04:00", "date_et": "2021-05-07"}
{"symbol": "ABBV", "publishedDate": "2021-05-07 17:36:21", "publisher": "GuruFocus", "title": "Guess Which Stocks Warren Buffett Bought: 1st-Quarter Contest", "image": "https://images.financialmodelingprep.com/news/guess-which-stocks-warren-buffett-bought-1stquarter-contest-20210507.jpg", "site": "gurufocus.com", "text": "GuruFocus runs a contest every quarter in which people guess the stocks they think Warren Buffett (Trades, Portfolio) might have bought.", "url": "https://www.gurufocus.com/news/1420109/guess-which-stocks-warren-buffett-bought-1stquarter-contest", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-07T17:36:21-04:00", "date_et": "2021-05-07"}
{"symbol": "ABBV", "publishedDate": "2021-05-08 06:04:00", "publisher": "The Motley Fool", "title": "Better Dividend Stock: AbbVie or Pfizer?", "image": "https://images.financialmodelingprep.com/news/better-dividend-stock-abbvie-or-pfizer-20210508.jpg", "site": "fool.com", "text": "Both big pharmaceutical companies have a lot to offer income investors.", "url": "https://www.fool.com/investing/2021/05/08/better-dividend-stock-abbvie-or-pfizer/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-08T06:04:00-04:00", "date_et": "2021-05-08"}
{"symbol": "ABBV", "publishedDate": "2021-05-08 06:25:00", "publisher": "The Motley Fool", "title": "Is It Too Late to Buy AbbVie Stock in 2021?", "image": "https://images.financialmodelingprep.com/news/is-it-too-late-to-buy-abbvie-stock-in-20210508.jpg", "site": "fool.com", "text": "It might not be too late to pick up shares of the big pharma company.", "url": "https://www.fool.com/investing/2021/05/08/is-it-too-late-to-buy-abbvie-stock-in-2021/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-08T06:25:00-04:00", "date_et": "2021-05-08"}
{"symbol": "ABBV", "publishedDate": "2021-05-08 07:45:00", "publisher": "Seeking Alpha", "title": "10 Of The Best Value Picks Among Dividend Aristocrats", "image": "https://images.financialmodelingprep.com/news/10-of-the-best-value-picks-among-dividend-aristocrats-20210508.jpg", "site": "seekingalpha.com", "text": "Dividend Aristocrats can be a great choice for investors looking for reliable income and stocks that can outperform during a recession. Not all Dividend Aristocrats are necessarily attractive at the same time, however.", "url": "https://seekingalpha.com/article/4425879-10-best-value-picks-among-dividend-aristocrats", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-08T07:45:00-04:00", "date_et": "2021-05-08"}
{"symbol": "ABBV", "publishedDate": "2021-05-10 08:30:00", "publisher": "PRNewsWire", "title": "Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio", "image": "https://images.financialmodelingprep.com/news/allergan-aesthetics-to-acquire-soliton-expanding-body-contouring-portfolio-20210510.jpg", "site": "prnewswire.com", "text": "IRVINE, Calif. and HOUSTON, May 10, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and Soliton (NASDAQ: SOLY) today announced a definitive agreement under which Allergan Aesthetics will acquire Soliton and RESONICTM, its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite.", "url": "https://www.prnewswire.com/news-releases/allergan-aesthetics-to-acquire-soliton-expanding-body-contouring-portfolio-301287307.html", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-10T08:30:00-04:00", "date_et": "2021-05-10"}
{"symbol": "ABBV", "publishedDate": "2021-05-10 16:24:00", "publisher": "PRNewsWire", "title": "SHAREHOLDER ALERT: WeissLaw LLP Investigates Soliton, Inc.", "image": "https://images.financialmodelingprep.com/news/shareholder-alert-weisslaw-llp-investigates-soliton-inc-20210510.jpg", "site": "prnewswire.com", "text": "NEW YORK, May 10, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Soliton, Inc. (\"Soliton\" or the \"Company\") (NASDAQ: SOLY) in connection with the proposed acquisition of the Company by Allergan Aesthetics, an AbbVie company (NYSE: ABBV). Under the terms of the merger agreement, Allergan Aesthetics will pay Soliton shareholders $22.60 in cash for each Soliton share that they own.", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-soliton-inc-301287875.html", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-10T16:24:00-04:00", "date_et": "2021-05-10"}
{"symbol": "ABBV", "publishedDate": "2021-05-11 14:12:11", "publisher": "GuruFocus", "title": "AbbVie Enters Growing Market for Tattoo Removal, Cellulite Treatment", "image": "https://images.financialmodelingprep.com/news/abbvie-enters-growing-market-for-tattoo-removal-cellulite-treatment-20210511.jpg", "site": "gurufocus.com", "text": "\"What were you inking?\"", "url": "https://www.gurufocus.com/news/1423501/abbvie-enters-growing-market-for-tattoo-removal-cellulite-treatment", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-11T14:12:11-04:00", "date_et": "2021-05-11"}
{"symbol": "ABBV", "publishedDate": "2021-05-11 19:32:13", "publisher": "Zacks Investment Research", "title": "3 Strong Dividend Stocks to Buy for Market Volatility and Inflation Fears", "image": "https://images.financialmodelingprep.com/news/3-strong-dividend-stocks-to-buy-for-market-volatility-20210511.jpg", "site": "zacks.com", "text": "Let's dive into three strong dividend-paying stocks that could be solid long-term holds.", "url": "https://www.zacks.com/stock/news/1537471/3-strong-dividend-stocks-to-buy-for-market-volatility-and-inflation-fears", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-11T19:32:13-04:00", "date_et": "2021-05-11"}
{"symbol": "ABBV", "publishedDate": "2021-05-12 05:52:00", "publisher": "The Motley Fool", "title": "The Best Warren Buffett Stocks to Buy With $300 Right Now", "image": "https://images.financialmodelingprep.com/news/the-best-warren-buffett-stocks-to-buy-with-300-20210512.jpg", "site": "fool.com", "text": "You can invest in several great companies that Buffett likes with only a modest upfront amount.", "url": "https://www.fool.com/investing/2021/05/12/the-best-warren-buffett-stocks-to-buy-with-300-rig/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-12T05:52:00-04:00", "date_et": "2021-05-12"}
{"symbol": "ABBV", "publishedDate": "2021-05-12 08:00:00", "publisher": "PRNewsWire", "title": "AbbVie to Present at the RBC Capital Markets Global Healthcare Conference", "image": "https://images.financialmodelingprep.com/news/abbvie-to-present-at-the-rbc-capital-markets-global-20210512.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill., May 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021.", "url": "https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-rbc-capital-markets-global-healthcare-conference-301289262.html", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-12T08:00:00-04:00", "date_et": "2021-05-12"}
{"symbol": "ABBV", "publishedDate": "2021-05-12 17:27:00", "publisher": "Business Wire", "title": "SOLITON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Soliton, Inc. - SOLY", "image": "https://images.financialmodelingprep.com/news/soliton-investor-alert-by-the-former-attorney-general-of-20210512.jpg", "site": "businesswire.com", "text": "NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Soliton, Inc. (NasdaqGS: SOLY) to AbbVie, Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Soliton will receive only $22.60 in cash for each share of Soliton that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whet", "url": "https://www.businesswire.com/news/home/20210512006041/en/SOLITON-INVESTOR-ALERT-by-the-Former-Attorney-General-of-Louisiana-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Soliton-Inc.---SOLY/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-12T17:27:00-04:00", "date_et": "2021-05-12"}
{"symbol": "ABBV", "publishedDate": "2021-05-13 10:43:46", "publisher": "Business Insider", "title": "AbbVie faces the biggest challenge yet to its best-selling medicine, Humira, as an unlikely Icelandic drugmaker launches a legal fight over 'outrageous' patents", "image": "https://images.financialmodelingprep.com/news/abbvie-faces-the-biggest-challenge-yet-to-its-bestselling-20210513.jpg", "site": "businessinsider.com", "text": "Pressure is rising on AbbVie as the $203 billion pharmaceutical company faces congressional scrutiny and a new legal battle over the core of its business. The Icelandic generic-drug specialist Alvotech launched a legal battle this week against AbbVie, challenging the patents that protect its best-selling medicine, Humira. Alvotech's goal is to launch a copycat version of Humira that would be sold at a cheaper price, known as a biosimilar.", "url": "https://www.businessinsider.com/alvogen-chairman-interview-suing-abbvie-humira-biosimilar-2021-5", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-13T10:43:46-04:00", "date_et": "2021-05-13"}
{"symbol": "ABBV", "publishedDate": "2021-05-14 06:20:00", "publisher": "The Motley Fool", "title": "3 Dividend Stocks That Pay You Better Than Coca-Cola Does", "image": "https://images.financialmodelingprep.com/news/3-dividend-stocks-that-pay-you-better-than-cocacola-20210514.jpg", "site": "fool.com", "text": "Income investors will find plenty to like about these reliable and generous dividend payers.", "url": "https://www.fool.com/investing/2021/05/14/3-dividend-stocks-that-pay-you-better-than-coca-co/", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-14T06:20:00-04:00", "date_et": "2021-05-14"}
{"symbol": "ABBV", "publishedDate": "2021-05-14 12:47:16", "publisher": "Zacks Investment Research", "title": "Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio", "image": "https://images.financialmodelingprep.com/news/why-abbvie-abbv-is-a-top-dividend-stock-for-20210514.jpg", "site": "zacks.com", "text": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?", "url": "https://www.zacks.com/stock/news/1551458/why-abbvie-abbv-is-a-top-dividend-stock-for-your-portfolio", "ticker": "ABBV", "event_date": "2021-04-30", "window_start": "2021-04-23", "window_end": "2021-05-14", "publishedDateET": "2021-05-14T12:47:16-04:00", "date_et": "2021-05-14"}
